ArticleThe Prostate2026

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.

Mayuko Kanayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.